Issue 40, 2022

Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells

Abstract

Promoting a senescent phenotype to suppress tumour progression may present an alternative strategy for treating cancer and encourages the development of positron emission tomography (PET) imaging biomarkers for assessing response to treatment. The accumulation of lipofuscin deposits in senescent cells is visualised using the pathology stain Sudan Black B (SBB) which is an emerging biomarker of senescence. We describe the design, synthesis and evaluation of [18F]fluoroethyltriazole-SBB ([18F]FET-SBB), a fluorine-18 radiolabelled derivative of SBB. The in vitro uptake of [18F]FET-SBB in a senescent cell line corelated with lipofuscin deposits; in vivo PET imaging and metabolite analysis confirm a favourable pharmacokinetic and metabolic profile for further studies of in vivo models of senescence.

Graphical abstract: Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells

Supplementary files

Article information

Article type
Paper
Submitted
21 Jul 2022
Accepted
06 Sep 2022
First published
15 Sep 2022
This article is Open Access
Creative Commons BY license

RSC Adv., 2022,12, 26372-26381

Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells

D. Brickute, C. Chen, M. Braga, C. Barnes, N. Wang, L. Allott and E. O. Aboagye, RSC Adv., 2022, 12, 26372 DOI: 10.1039/D2RA04535D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements